We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

1 hedge funds and large institutions have $1.9M invested in Sonnet BioTherapeutics in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

58% less capital invested

Capital invested by funds: $4.54M → $1.9M (-$2.65M)

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TDC
Thompson Davis & Co
Virginia
+$1.18M

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$1.18M
2
EI
EAM Investors
California
-$981K
3
CCM
Coe Capital Management
Illinois
-$717K
4
Citadel Advisors
Citadel Advisors
Florida
-$90K
5
Walleye Trading
Walleye Trading
New York
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
TDC
1
Thompson Davis & Co
Virginia
$396K +$1.18M +1 New
Bank of America
2
Bank of America
North Carolina
$300K -$1.18M -1 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
$229K – – –
Millennium Management
4
Millennium Management
New York
$227K – – –
IC
5
Intersect Capital
California
$136K – – –
BIT
6
BlackRock Institutional Trust
California
$111K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$101K – – –
EVC
8
Eidelman Virant Capital
Missouri
$88K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$72K – – –
VKH
10
Virtu KCG Holdings
New York
$67K – – –
GHAM
11
Gilman Hill Asset Management
Connecticut
$53K – – –
CDH
12
Charles D. Hyman
$49K – – –
CL
13
CSS LLC
Illinois
$26K – – –
Northern Trust
14
Northern Trust
Illinois
$19K – – –
TSS
15
Two Sigma Securities
New York
$15K – – –
BIM
16
BlackRock Investment Management
Delaware
$5K – – –
UBS Group
17
UBS Group
Switzerland
$1K – – –
EI
18
EAM Investors
California
– -$981K -1 Closed
Citadel Advisors
19
Citadel Advisors
Florida
– -$90K – –
CCM
20
Coe Capital Management
Illinois
– -$717K – –
Morgan Stanley
21
Morgan Stanley
New York
– -$3K – –
Walleye Trading
22
Walleye Trading
New York
– -$6K – –

SONN Hedge Fund Activity: Q3 2015 in Review

1 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2015, worth a combined $1.9M — down 58% from $4.54M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SONN and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Thompson Davis & Co, opening a new position worth an estimated $1.18M. The largest seller was Bank of America, exiting entirely with an estimated $1.18M sold.

  • 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q3 2015, down from 2 in Q2 2015.
  • Funds reported $1.9M of Sonnet BioTherapeutics stock for Q3 2015, down 58% quarter-over-quarter.
  • 1 fund opened new Sonnet BioTherapeutics positions in Q3 2015 and 2 closed out, a net change of -1 holder.
  • The largest Sonnet BioTherapeutics buyer in Q3 2015 was Thompson Davis & Co, an estimated $1.18M added.
  • The largest Sonnet BioTherapeutics seller in Q3 2015 was Bank of America, an estimated $1.18M sold.

Based on aggregated 13F filings for Q3 2015.